Certara, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jon Resnick
- Full Time Employees
- 1,576
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 4 Radnor Corporate Center Radnor PA United States of America 08540
- IPO Date
- Dec 11, 2020
- CIK
- 0001827090
- Website
- certara.com
- Similar Companies
- Business
- Certara, Inc. (Nasdaq: CERT) provides biosimulation software, technology-enabled services, and solutions for model-informed drug development (MIDD) in the biopharmaceutical industry; its core offerings include mechanistic and empirical biosimulation platforms such as Simcyp PBPK Simulator; empirical PK/PD biosimulation platform; scientific informatics platforms like D360 and Chemaxon products including Design Hub and JChem Engines; clinical outcomes databases; regulatory submissions authoring and management software; market access communication platforms; data standardization and compliance software; and services encompassing drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, health economics and outcomes research (HEOR), and real-world evidence solutions. Founded in 2008 through the combination of Tripos International and Pharsight Corporation and headquartered at 4 Radnor Corporate Center, Suite 350, Radnor, Pennsylvania, the company operates globally with offices in the U.S., Canada, U.K., France, Germany, Switzerland, India, Japan, China, Australia, the Netherlands, and the Philippines, serving over 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across more than 70 countries. In recent developments, Certara completed the acquisition of Chemaxon in October 2024 to enhance its scientific informatics and predictive biosimulation capabilities from discovery through commercialization, integrating precision chemistry tools into its D360 applications and Simcyp simulator while leveraging Certara.AI for improved drug discovery insights; the company relocated its corporate headquarters to Radnor, Pennsylvania in 2024 to support workforce growth and strengthen its presence in the life sciences hub near Philadelphia; and it reported preliminary first-quarter 2025 financial results in April 2025 with revenue of $106.0 million, up from $96.7 million in the prior year, alongside 12% bookings growth and a $100 million share repurchase authorization.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Certara Announces CFO Transition
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT